论文部分内容阅读
ＨｙｐｅｒＧＡＭ＋ＣＦ进入Ⅰ／Ⅱ期临床研究尤尼瓦克－基因酶（Ｕｎｉｖａｘ－Ｇｅｎｚｙｍｅ）公司已在美国开始对ＨｙｐｅｒＧＡＭ＋ＣＦ进行Ｉ／Ⅱ期临床试验。它是一种特殊的多克隆抗体，可用于预防和治疗囊性纤维变性病人的绿脓杆菌感染。除对这些感染提供被动免疫...
HyperGAM + CF enters phase I / II clinical studies Univax-Genzyme has begun clinical phase I / II trials of HyperGAM + CF in the United States. It is a special polyclonal antibody that can be used to prevent and treat Pseudomonas aeruginosa infections in patients with cystic fibrosis. In addition to passive immunization of these infections ...